Active
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma:
Malignant Peripheral Nerve Sheath Tumor (MPNST) either Sporadic or NF1 Associated
Drug:
Bevacizumab and Everolimus
Accrual Status:
Not Recruiting
Overall Study Principal Investigator:
Brigitte C. Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute